OC
AH

Oppenheimer & Co’s Accretive Health AH Stock Holding History

Oppenheimer & Co’s Portfolio AH Stock Details AH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-13,100
Closed -$105K – 1556
2014
Q1 		$105K Sell
13,100
-1,000
-7% -$8.86K ﹤0.01% 1338
2013
Q4 		$129K Buy
14,100
+100
+0.7% +$861 ﹤0.01% 1288
2013
Q3 		$127K Buy
14,000
+1,124
+9% +$11.2K ﹤0.01% 1225
2013
Q2 		$140K Buy
+12,876
New +$135K 0.01% 1166

Other funds holding AH

JRP
Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RMC
Regis Management Company Menlo Park, California $331M AUM 14.13% 1-Year Est. Return
BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
ECM
EII Capital Management New York $774K AUM 22.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
MIM
Merion Investment Management Bay Harbor Islands, Florida $1.26M AUM 28.57% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
SCM
Stonebridge Capital Management Los Angeles, California $208M AUM

Oppenheimer & Co's AH Position: Q2 2014 in Review

Oppenheimer & Co sold out of Accretive Health (AH) in Q2 2014, closing a stake of 13,100 shares — an estimated $105K sold.

Oppenheimer & Co first reported a position in AH in Q2 2013 and held it in 4 quarters. The position peaked at $140K in Q2 2013. 12 funds tracked by Wall St. Rank hold AH as of Q2 2014.

  • Oppenheimer & Co reported no remaining Accretive Health position as of Q2 2014 after selling out during the quarter.
  • Oppenheimer & Co sold 13,100 Accretive Health shares in Q2 2014, an estimated $105K.
  • Oppenheimer & Co first reported a position in Accretive Health in Q2 2013 and held it in 4 quarters.
  • Oppenheimer & Co's Accretive Health position peaked at $140K in Q2 2013.
  • 12 funds tracked by Wall St. Rank held Accretive Health as of Q2 2014.

Based on Oppenheimer & Co's 13F filing for Q2 2014, filed 14 Aug 2014.